GLPG1690
GLPG1690-CL-304
Phase 3 small_molecule terminated
Quick answer
GLPG1690 for Idiopathic Pulmonary Fibrosis is a Phase 3 program (small_molecule) at Lakefront Biotherapeutics NV with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Idiopathic Pulmonary Fibrosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated